Drugs / XmAb24306
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05646836 | Mar 2023 → Nov 2026 expected | plasma cell myeloma | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05243342 | Apr 2022 → Jul 2024 | plasma cell myeloma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04250155 | Mar 2020 → May 2026 | cancer | Genentech, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-04-18 | Xencor, Inc. | Results Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting xencor.com ↗
Data show that the engineered complex enhanced the duration and magnitude of T and NK cell proliferation in vitro and in vivo. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-04-18 | Xencor, Inc. | Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting xencor.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XmAb24306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05243342 ↗ |
| Route | Intravenous | “Participants will receive intravenous (IV) XmAb24306.” NCT04250155 ↗ |